Beijing Quietly Charms Both MNCs And Specialty Biotechs In Effort To Establish China's Bio Valley
This article was originally published in PharmAsia News
BEIJING - Aiming to carve a leading position in China's nascent biotech industry, Beijing has embarked on a project to grow the industry more than two-fold in three years. Dubbed the "G20 Project," the Beijing Leap-forward Development Program for Biopharmaceutical Industry seeks to transform the capital city into China's hub for biotech R&D and manufacturing
You may also be interested in...
A H7N9 diagnostic testing agent developed by Beijing Kinghawk Pharmaceutical Co. Ltd and Beijing SinoMedgene Technology Co. Ltd. was approved by Beijing FDA under the green channel approval process. The test cuts the time for results to less than three hours, down from six hours.
Merck Unveils $1.5 Billion Expansion In China With New Beijing R&D Center; Plans To Double R&D Team By 2014
While many Big Pharmas are cutting R&D budgets in response to patent cliffs, Merck is investing $1.5 billion in R&D in China, in what could be the largest ever pharma R&D investment in the country.
SHANGHAI - Nanjing, China's Simcere Pharmaceutical Group reported a slowdown in sales for the second quarter, pointing to intense competition from the spread of Anhui province's tender model for essential drugs and price cuts on products included in the National Drug Reimbursement List